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Background
Few longitudinal data are available on bone mass changes
in children and adolescents treated with glucocorticoids
(GCs). The aim of our study is to verify their long-term
effects on bone mass.
Materials and methods
266 patients (3–20 years) on long-term treatment with
GCs for chronic diseases were followed with evaluation of
bone mineral density (BMD) for at least 3 years (3 – 14
years).
BMD was measured with DXA at lumbar spine and on
total body and expressed as the Z-score. BMAD was calcu-
lated.
Results
GCs had a major effect on trabecular bone independently
by the disease and age of patients. This effect is dose
related: cumulative dose GCs < 10 g = decrease of 23%; 10
– 30 g = -40%; > 30 g = -68%. A significant correlation was
found between spine Z-score vs cumulative GCs (p <
0.001).
Bone loss of spine was higher during the first year of GCs
and continues during time at a lower degree (16% the first
year, 6% second-fifth year, 3.5% over the fifth year).
GCs influenced BMD differently in relation to age at start
of therapy and the disease.
83 patients had at least 1 fragility fractures and 33 had
more than 1 fracture. A total of 161 fragility fractures
occurred in the group.
Conclusion
GCs induce bone loss and fractures in the young and alter
the bone accrual. The relationship between BMD and
cumulative dose of steroids clearly underline the absolute
need to use the minimum effective dose of GCs.
from 15th Paediatric Rheumatology European Society (PreS) Congress
London, UK. 14–17 September 2008
Published: 15 September 2008
Pediatric Rheumatology 2008, 6(Suppl 1):S16 doi:10.1186/1546-0096-6-S1-S16
<supplement> <title> <p>15<sup>th </sup>Paediatric Rheumatology European Society (PreS) Congress</p> </title> <editor>Wietse Kuis, Patricia Woo, Angelo Ravelli, Hermann Girschick, Michaël Hofer, Johannes Roth, Rotraud K Saurenmann, Alberto Martini, Pavla Dolezova, Janjaap van der Net, Pierre Quartier, Lucy Wedderburn and Jan Scott</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/PDF/1546-0096-6-S1-full.pdf">here</a>.</note> </supplement>
This abstract is available from: http://www.ped-rheum.com/content/6/S1/S16
© 2008 Biggioggero et al; licensee BioMed Central Ltd. 